Effects of norketamine enantiomers in rodent models of persistent pain

Pharmacology Biochemistry and Behavior

Volumn 90, Issue 4, 2008, Pages 676-685

  Holtman Jr , Joseph R ^a,b   Crooks, Peter A ^b   Johnson Hardy, Jaime K ^a   Hojomat, Marhaba ^c   Kleven, Mark ^c   Wala, Elzbieta P ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b University of Kentucky   (United States)

^c Yaupon Therapeutics Inc   (United States)

Author keywords

Chronic constriction nerve injury rodent model; Formalin test; NMDA receptor antagonist; Norketamine antinociception; Norketamine enantiomers; Norketamine side effects

Indexed keywords

KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NORKETAMINE;

ALLODYNIA; ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; HYPERALGESIA; MALE; NERVE INJURY; NONHUMAN; PAIN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; BEHAVIOR, ANIMAL; CHRONIC DISEASE; CONSTRICTION, PATHOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; FORMALDEHYDE; HOT TEMPERATURE; HYPERALGESIA; KETAMINE; MALE; MOTOR ACTIVITY; PAIN; PAIN MEASUREMENT; PERIPHERAL NERVOUS SYSTEM DISEASES; PHYSICAL STIMULATION; POSTURAL BALANCE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; STEREOISOMERISM; STEREOTYPED BEHAVIOR;

RODENTIA;

EID: 48749108718     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2008.05.011     Document Type: Article

References (53)

1. Arendt-Nielsen L., Nielsen J., Petersen-Felix S., Schnider T.W., and Zbinden A.M. Effect of racemic mixture and the S(+)-isomer of ketamine on temporal and spatial summation of pain. Br J Anesth 77 (1996) 625-631
2. Backonja M., Arndt G., Gombar K.A., Check B., and Zimmermann M. Response of chronic pain syndromes to ketamine: a preliminary study. Pain 56 (1994) 51-56
3. Bennett G. Update on the neurophysiology of pain transmission and modulation: focus on the NMDA receptor. J Pain Symptom Management 19 (2000) S2-S6
4. Bennett G., and Xie Y. A peripheral mononeuropathy in rat that produced disorders of pain sensation like those seen in man. Pain 33 (1988) 87-107
5. Berrino L., Oliva P., Massimo F., Aurill C., Maione S., Grella A., and Rossi F. Antinociceptive effect in mice of intraperitoneal N-methyl-d-aspartate receptor antagonists in the formalin test. Eur J Pain 7 2 (2003) 131-137
6. Bushnell T.G., and Craig J. Response to chronic neuropathic syndromes to ketamine. A role of norketamine?. Pain 60 (1995) 115
7. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., and Yaksh T.L. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53 (1994) 55-63
8. Chaplan S.R., Malmberg A.B., and Yaksh T.L. Efficacy of spinal NMDA receptor antagonism in formalin hyperalgesia and nerve injury evoked allodynia in the rat. J Pharmacol Exp Ther 280 (1997) 829-838
9. Christoph T., Sciene K., Englberger W., Parsons C.G., and Chizh B.A. The antiallodynic effect of NMDA antagonists in neuropathic pain outlast the duration of the in vivo NMDA antagonism. Neuropharmacology 51 (2006) 12-17
10. Clements J.A., Nimmo W.S., and Grant I.S. Bioavailability, pharmacokinetics and analgesic activity of ketamine in humans. J Pharmacol Sci 71 (1982) 539-542
11. Coderre T.J., and Melzack R. The contribution of excitatory amino acids to central sensitization and persistent nociception after formalin-induced tissue injury. J Neurosci 12 (1992) 3665-3670
12. Cohen M.L., and Trevor A.J. On the cerebral accumulation of ketamine and the relationship between metabolism of drug and its pharmacological effects. J Pharmacol Exp Ther 189 (1974) 351-358
13. Cohen M.L., Chan S.L., Way W.L., and Trevor A.J. Distribution in the brain and metabolism of ketamine in the rat after intravenous administration. Anesthesiology 39 (1973) 370-376
14. Davar G., Hama A., Deykin A., Vos K., and Maciewicz R. MK-801 blocks the development of thermal hyperalgesia in a rat model of experimental painful neuropathy. Brain Res 553 (1991) 327-330
15. Edwards S.R., and Mather L.E. Tissue uptake of ketamine and norketamine enantiomers in the rat. Indirect evidence for extrahepatic metabolic inversion. Life Sci 69 (2001) 2051-2066
16. Ebert B., Mikkalsen S., Thorkildsen C., and Borgbjerg F. Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur J Pharmacol 333 (1997) 99-104
17. Eide P., Stubhaug A., and Jorum E. Relief of post-herpetic neuralgia with the N-methyl-d-aspartate (NMDA) receptor antagonist ketamine: a double-blind, cross-over comparison with morphine and placebo. Pain 58 (1994) 347-354
18. Eisenberg E., LaCross S., and Strassman A.M. The clinically tested N-methyl-d-aspartate receptor antagonist memantine blocks and reverses thermal hyperalgesia in a rat model of painful mono-neuropathy. Neurosci Letters 187 (1995) 17-20
19. Engelhardt W. Aufwachverhalten und psychomimetishe reactionen nach S(+)-ketamin. Anesthesist 46 (1997) 38-42
20. Fisher K., Coderre T., and Hagen N. Targeting the N-methyl-d-aspartate receptor for chronic pain management: preclinical animal studies, recent clinical experience, and future research directions. J Pain Symptom Management 20 (2000) 358-373
21. Grant I.S., Nimmo W.S., and Clemments J.A. Pharmacokinetics and analgesic effects of i.m. and oral ketamine. Br J Anesth 53 (1981) 805-810
22. Hargreaves K., Dubner R., Brown F., Flores C., and Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32 (1988) 77-88
23. Hustveit O., Maurset A., and Oye I. Interaction of chirial forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol Toxicol 77 (1995) 355-359
24. Hong S.C., and Davisson J.N. Stereochemical studies of demethylated ketamine enantiomers. J Pharm Sci 71 (1982) 912-914
25. Johnson B.W. Pain mechanism: anatomy, physiology, and neurochemistry. In: Raja P.P. (Ed). Practical management of pain (2000), Mosby, Inc, St. Louis 117-143
26. Kharasch E.D., and Labroo R. Metabolism of ketamine stereoisomers by human liver microsomes. Anesthesiology 77 (1992) 1201-1207
27. Kim Y.I., Na H.S., Yoon Y.W., Han H.C., Ko K.H., and Hong S.K. NMDA receptors are important for both mechanical and thermal allodynia from peripheral nerve injury in rats. NeuroReport 8 (1997) 2148-2153
28. Leung L.Y., and Baillie T.A. Comparative pharmacology in the rat of ketamine and its two principal metabolites, norketamine and (Z)-6-hydroxynorketamine. J Med Chem 29 (1986) 2396-2399
29. Leung L.Y., and Baillie T.A. Stereoselective metabolism of norketamine, the N-demethylated metabolite of ketamine, in rat liver microsomes. In: Domino E.F., and Kamenka J.M. (Eds). Sigma and phencylidine-like compounds as molecular probes in biology (1988), NPP Books, Ann Arbor 607-617
30. Liu J., Ji X.Q., and Zhu X.Z. Comparison of psychic emergence reactions after (±)-ketamine and (+) -ketamine in mice. Life Sci 78 (2006) 1839-1844
31. Malinovsky J.M., Cozian S.A., Lapage J.Y., and Pinaud M. Ketamine and norketamine plasma concentrations after IV and nasal and rectal administration in children. Brit J Anesth. 77 (1996) 203-207
32. Mao J., Price D.D., Haves R.L., Lu J., and Mayer D.J. Intrathecal treatment with dextrophan or ketamine potently reduced pain-related behaviors in a rat model of peripheral mononeuropathy. Brain Res 605 (1993) 164-168
33. Marietta M.P., Way W.L., Castagnoli N., and Trevor A.J. On the pharmacology of ketamine enantiomers in the rat. J Pharmacol Exp Ther 2002 (1977) 157-165
34. Medvediev I.O., Malyshkin A.A., Belozertseva I.V., Sukhotina I.A., Sevostianova N.Y., Aliev K., et al. Effects of low-affinity NMDA receptor channel blockers in two rat models of chronic pain. Neuropharmacology 47 (2004) 175-183
35. Qian J., Brown S.D., and Carlton S.M. Systemic ketamine attenuates nociceptive behaviors in a rat model of peripheral neuropathy. Brain Res 715 (1996) 51-62
36. Parson C. NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol 429 (2001) 71-78
37. Randal L., and Selitto J. A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn Ther 111 (1957) 409-419
38. Ryder S., Way W.L., and Trevor A.J. Comparative pharmacology of the optical isomers of ketamine in mice. Eur J Pharmacol 49 (1978) 15-23
39. Sang C.N. NMDA-receptor antagonists in neuropathic pain: experimental methods to clinical trials. J Pain Symptom Management 19 (2000) S21-25
40. Schuttler J., Zsigmond E.K., and White P.F. Ketamine and its isomers. In: White P.F. (Ed). Textbook of intravenous anesthesia (1997), Williams and Wilkins, Baltimore 171-188
41. Shimoyama M., Shimoyama N., Gorman A.L., Elliott K.J., and Intrussi C.E. Oral ketamine is antinociceptive in the rat formalin test: role of the metabolite, norketamine. Pain 81 (1999) 85-93
42. Sturgeon R., Fessler R., and Meltzer H. Behavioral rating scales for assessing phencyclidine-induced locomotor activity, stereotyped behavior and ataxia in rats. Eur J Pharmacol 59 (1979) 169-179
43. Tal M., and Bennett G.J. Neuropathic pain sensations are differentially sensitive to dextrorphan. NeuroReport 5 (1994) 1438-1440
44. Tallarida R.J., and Murray R.B. Manual of pharmacological calculations with computer program (1987), Springler-Verlag, New York
45. Theurillat R., Knobloch M., Levionnois O., Larenza P., Mevissen M., and Thormann W. Characterization of the stereoselective biotransformation of ketamine to norketamine via determination of their enantiomers in equine plasma by capillary electrophorese. Electrophoresis 26 (2005) 3942-3951
46. Vaccarino A.L., Marek P., Kest B., Weber E., Keana J.F., and Liebeskind J.C. NMDA receptor antagonists, MK-801 and ACEA-1011, prevent the development of tonic pain following subcutaneous formalin. Brain Res 615 (1993) 331-334
47. Vollenweider F.X., Leenders K.L., Qye L., Hell D., and Angst J. Differential psychopathology and patterns of cerebral glucose utilization produced by S- and R-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropharmacol 7 (1997) 25-38
48. Vranken J.H., Troost D., Wefener J.T., Kruist M.R., and van der Vegt M.T. Neuropathological findings after continuous intrathecal administration of S(+)-ketamine for management of neuropathic cancer pain. Pain 117 (2005) 231-235
49. White P.F., Ham J., Way W.L., and Trevor A.J. Pharmacology of ketamine isomers in surgical patients. Anesthesiology 52 (1980) 2312-2339
50. White P.F., Schuttler J., Shafer A., Stanski D.R., Honai Y., and Trevor A.J. Pharmacology of ketamine isomers in surgical patients. Br J Anaesth 57 (1985) 197-203
51. Wheeler-Aceto H., and Cowan A. Standardization of the rat paw formalin test for evaluation of analgesics. Psychopharmacol 104 (1991) 35-44
52. Yamamoto T., and Yaksh T.L. Spinal pharmacology of thermal hyperesthesia induced by constriction injury of sciatic nerve. Excitatory amino acid antagonists. Pain 49 (1992) 121-128
53. Yanagihara Y., Ohtani M., Kariya S., Uchino K., Hiraishi T., Ashizawa N., et al. Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharm Drug Disp 24 (2003) 37-43